Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04939818
Other study ID # NOV-0200
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 14, 2021
Est. completion date September 15, 2022

Study information

Verified date March 2023
Source Novoic Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The primary objective of the study is to evaluate the feasibility of eliciting continuous narrative speech in different neurodegenerative and psychiatric indications, using remote, self-administered speech tasks, as measured by the average length of speech elicitation for each speech task during the first week of self-assessment. Secondary objectives include (1) evaluating the reliability of speech tasks in the remote self-administered setting, as measured by the intra- and inter-subject variance; (2) accessing the adherence of speech tasks in this setting, as measured by the subject average fraction of days during the first week, where at least one task response is submitted; (3) evaluating the feasibility of using speech tasks in the setting of a telemedicine videoconference, as measured by the average length of speech elicited in each group; (4) evaluate whether a set of acoustic and linguistic patterns can detect each indication, compare to either a control group or all other indications, as measured by the area under the receiver operating characteristic curve (AUC), sensitivity, specificity and Cohen's kappa of the relevant binary classifier; (5) evaluating how the performance of such algorithms can be impacted by speaker and environment covariates, as measured by the Kendall rank correlation coefficient of the AUC of each classifier and each of age group, gender and speech-to-reverberation modulation energy ratio.


Recruitment information / eligibility

Status Completed
Enrollment 172
Est. completion date September 15, 2022
Est. primary completion date September 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Willing to participate, having been provided full information about the study components and details. - Native language is English. - Has the capacity to provide fully informed consent. - Has access to and able to use, or has a caregiver who has access to and able to use a smartphone device running an operation system of iOS 11.0 or later, or Android 7.0 or later. - Able to use, or has a caregiver who is able to use a personal computer, notebook or tablet. - Has access to a personal computer, notebook or tablet that is (1) Running an operating system of: macOS X with macOS 10.9 or later; OR Windows 7 or above; AND (2) Capable of audio recording; AND (3) Able to connect to the internet; AND (4) Have access to one of following internet browser software: Internet Explorer version 11 or above; OR Microsoft Edge version 12 or above; OR Firefox version 27 or above; OR Google Chrome version 30 or above; OR Safari version 7 or above. Exclusion Criteria: - Diagnosis of alcohol or drug use disorder; - History or presence of stroke within the past 2 years; - Documented history of transient ischemic attack or unexplained loss of consciousness within the last 12 months. - At risk of suicide: score of 10 or above on the PHQ scale, and 10 or above on the MINI suicide questionnaire

Study Design


Related Conditions & MeSH terms

  • Alzheimer Disease
  • Amyotrophic Lateral Sclerosis
  • Aphasia
  • Aphasia, Primary Progressive
  • Bipolar Disorder
  • Cognitive Dysfunction
  • Dementia
  • Dementia With Lewy Bodies
  • Dementia, Vascular
  • Depressive Disorder
  • Depressive Disorder, Major
  • Disease
  • Frontotemporal Dementia
  • Lewy Body Disease
  • Major Depressive Disorder
  • Mental Disorders
  • Mild Cognitive Impairment
  • Motor Neuron Disease
  • Parkinson Disease
  • Pick Disease of the Brain
  • Primary Progressive Aphasia
  • Problem Behavior

Locations

Country Name City State
United Kingdom King's College Hospital NHS Foundation Trust London Greater London
United Kingdom South London and Maudsley NHS Foundation Trust London Greater London

Sponsors (2)

Lead Sponsor Collaborator
Novoic Limited King's College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The average length of speech elicitation for each speech task (in seconds) during the first week of self-assessments. One week
Secondary The intra-subject variance of length of speech elicitation for each speech task during the first week of self-assessments, as measured by Coefficients of Individual Agreement (CIA). One week
Secondary The inter-subject variance of length of speech elicitation for each speech task during the first week of self-assessments, as measured by Coefficients of Individual Agreement (CIA). One week
Secondary The subject average fraction of days during the first week of remote, self-assessment, where participants submitted at least one task response. One week
Secondary The average length of speech elicitation for each speech task, during the telemedicine video conference. baseline
Secondary The AUC of the binary classifier distinguishing between the AD diagnostic groups vs the applicable control group. One month
Secondary The AUC of the binary classifier distinguishing between the Dementia with Lewy Bodies (LBD) diagnostic groups vs the applicable control group. One month
Secondary The AUC of the binary classifier distinguishing between the PD diagnostic groups vs the applicable control group. One month
Secondary The AUC of the binary classifier distinguishing between the MND diagnostic groups vs the applicable control group. One month
Secondary The AUC of the binary classifier distinguishing between the Frontotemporal Dementia and Vascular Dementia (FTD/VCI) diagnostic groups vs the applicable control group. One month
Secondary The AUC of the binary classifier distinguishing between the MDD diagnostic groups vs the applicable control group. One month
Secondary The AUC of the binary classifier distinguishing between the BD diagnostic groups vs the applicable control group. One month
Secondary The sensitivity of the binary classifier distinguishing between the AD diagnostic groups vs the applicable control group. One month
Secondary The sensitivity of the binary classifier distinguishing between the LBD diagnostic groups vs the applicable control group. One month
Secondary The sensitivity of the binary classifier distinguishing between the PD diagnostic groups vs the applicable control group. One month
Secondary The sensitivity of the binary classifier distinguishing between the MND diagnostic groups vs the applicable control group. One month
Secondary The sensitivity of the binary classifier distinguishing between the FTD/VCI diagnostic groups vs the applicable control group. One month
Secondary The sensitivity of the binary classifier distinguishing between the MDD diagnostic groups vs the applicable control group. One month
Secondary The sensitivity of the binary classifier distinguishing between the BD diagnostic groups vs the applicable control group. One month
Secondary The specificity of the binary classifier distinguishing between the AD diagnostic groups vs the applicable control group. One month
Secondary The specificity of the binary classifier distinguishing between the LBD diagnostic groups vs the applicable control group. One month
Secondary The specificity of the binary classifier distinguishing between the PD diagnostic groups vs the applicable control group. One month
Secondary The specificity of the binary classifier distinguishing between the MND diagnostic groups vs the applicable control group. One month
Secondary The specificity of the binary classifier distinguishing between the FTD/VCI diagnostic groups vs the applicable control group. One month
Secondary The specificity of the binary classifier distinguishing between the MDD diagnostic groups vs the applicable control group. One month
Secondary The specificity of the binary classifier distinguishing between the BD diagnostic groups vs the applicable control group. One month
Secondary The Cohen's kappa of the binary classifier distinguishing between the AD diagnostic groups vs the applicable control group. One month
Secondary The Cohen's kappa of the binary classifier distinguishing between the LBD diagnostic groups vs the applicable control group. One month
Secondary The Cohen's kappa of the binary classifier distinguishing between the PD diagnostic groups vs the applicable control group. One month
Secondary The Cohen's kappa of the binary classifier distinguishing between the FTD/VCI diagnostic groups vs the applicable control group. One month
Secondary The Cohen's kappa of the binary classifier distinguishing between the MDD diagnostic groups vs the applicable control group. One month
Secondary The Cohen's kappa of the binary classifier distinguishing between the BD diagnostic groups vs the applicable control group. One month
Secondary The AUC of the binary classifier distinguishing between the following diagnostic groups vs all other diagnostic groups (pooled): AD, LBD, PD, MND, FTD/VCI, MDD, BD. One month
Secondary The sensitivity of the binary classifier distinguishing between the following diagnostic groups vs the other groups (pooled): AD, LBD, PD, MND, FTD/VCI, MDD, BD. One month
Secondary The specificity of the binary classifier distinguishing between the following diagnostic groups vs the other groups (pooled): AD, LBD, PD, MND, FTD/VCI, MDD, BD. One month
Secondary The Cohen's kappa of the binary classifier distinguishing between the following diagnostic groups vs the other groups (pooled): AD, LBD, PD, MND, FTD/VCI, MDD, BD. One month
Secondary For each classifier/regressor in the outcomes, the correlation between the AUC/CIA and each age group, gender and speech-to-reverberation modulation energy ratio group, as measured by the Kendall rank correlation coefficient. One month
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A